NMD Pharma
NMD Pharma develops small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels to treat neuromuscular diseases where muscle activation is failing. The company utilizes an experimental platform focused on ion channel function and electrophysiology to address muscle weakness and fatigue. Its primary clinical focus includes myasthenia gravis, spinal muscular atrophy, Charcot-Marie-Tooth disease, and sarcopenia.
Visit websiteAarhus, Denmark
Biotechnology
Pharmaceuticals
Life Sciences
Healthcare
Funding summary
- Total raised
- €35.0M
- Funding rounds
- 1
Investors in NMD Pharma
Investors on record for NMD Pharma. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like NMD Pharma?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors